Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2CNS 2Sarcoma 1Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 5Adenocarcinoma of Lung 5Lymphoma, Large-Cell, Anaplastic 2Hematologic Neoplasms 2Granuloma, Plasma Cell 2Rhabdomyosarcoma 1Noonan Syndrome 6 1Neuroblastoma 1Neoplasms 1Melanoma 1Lymphoma, B-Cell 1Glioblastoma 1Brain Neoplasms 1ALK-positive Non-small Cell Lung Cancer 1ALK-positive NSCLC 1

Interventions

Cyclophosphamide 27fludarabine phosphate 19Whole-Body Irradiation 18Peripheral Blood Stem Cell Transplantation 18Etoposide 17Rituximab 15Brentuximab Vedotin 15Mycophenolic Acid 14Tacrolimus 13Doxorubicin 12Vincristine 11Prednisone 11Methotrexate 11Busulfan 11Melphalan 9Antilymphocyte Serum 9Cyclosporine 8Filgrastim 6Carboplatin 6Sirolimus 5Radiotherapy 5Lenalidomide 5Gene Expression Profiling 5Cytarabine 5merphos 4Vorinostat 4Immunohistochemistry 4Ifosfamide 4Gemcitabine 4Flow Cytometry 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Lymphoma, Large-Cell, Anaplastic × ceritinib × Clear all
NCT01742286 2020-06-09

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

Novartis

Phase 1 Completed
83 enrolled 30 charts
CNSLymphoidPlasma cellSarcoma

Granuloma, Plasma Cell, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Lymphoma, Large-Cell, Anaplastic

NCT02465528 2019-12-27

Ceritinib Rare Indications Study in ALK+ Tumors

Novartis

Phase 2 Terminated
22 enrolled 16 charts
CNSLymphoidOther hematologic neoplasmPlasma cell

Glioblastoma, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡